KONINKLIJKE PHILIPS NV (PHI1.DE) Stock Fundamental Analysis
FRA:PHI1 - Deutsche Boerse Ag - NL0000009538 - Common Stock - Currency: EUR
We assign a fundamental rating of 3 out of 10 to PHI1. PHI1 was compared to 55 industry peers in the Health Care Equipment & Supplies industry. PHI1 may be in some trouble as it scores bad on both profitability and health. PHI1 has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
PHI1 had positive earnings in the past year.
PHI1 had a positive operating cash flow in the past year.
In multiple years PHI1 reported negative net income over the last 5 years.
PHI1 had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
PHI1's Return On Assets of -1.43% is on the low side compared to the rest of the industry. PHI1 is outperformed by 62.75% of its industry peers.
The Return On Equity of PHI1 (-3.54%) is worse than 62.75% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -3.54% | ||
| ROIC | N/A |
ROA(3y)1.3%
ROA(5y)2.5%
ROE(3y)2.33%
ROE(5y)5.25%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PHI1's Operating Margin has declined in the last couple of years.
PHI1 has a worse Gross Margin (41.56%) than 72.55% of its industry peers.
PHI1's Gross Margin has been stable in the last couple of years.
PHI1 does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.56% |
OM growth 3Y-40.52%
OM growth 5Y-26.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.47%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
PHI1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for PHI1 has been reduced compared to 1 year ago.
Compared to 5 years ago, PHI1 has more shares outstanding
PHI1 has a worse debt/assets ratio than last year.
2.2 Solvency
PHI1 has an Altman-Z score of 1.63. This is a bad value and indicates that PHI1 is not financially healthy and even has some risk of bankruptcy.
PHI1 has a Altman-Z score of 1.63. This is comparable to the rest of the industry: PHI1 outperforms 45.10% of its industry peers.
The Debt to FCF ratio of PHI1 is 7.27, which is on the high side as it means it would take PHI1, 7.27 years of fcf income to pay off all of its debts.
PHI1 has a Debt to FCF ratio (7.27) which is in line with its industry peers.
PHI1 has a Debt/Equity ratio of 0.60. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
PHI1 has a Debt to Equity ratio of 0.60. This is in the lower half of the industry: PHI1 underperforms 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 7.27 | ||
| Altman-Z | 1.63 |
ROIC/WACCN/A
WACC5.99%
2.3 Liquidity
A Current Ratio of 1.16 indicates that PHI1 should not have too much problems paying its short term obligations.
PHI1 has a Current ratio of 1.16. This is in the lower half of the industry: PHI1 underperforms 76.47% of its industry peers.
A Quick Ratio of 0.74 indicates that PHI1 may have some problems paying its short term obligations.
PHI1 has a Quick ratio of 0.74. This is in the lower half of the industry: PHI1 underperforms 70.59% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
PHI1 shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 3.65%.
Measured over the past years, PHI1 shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.67% on average per year.
Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -2.65% in the last year.
Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 0.05% on average per year.
EPS 1Y (TTM)3.65%
EPS 3Y-15.7%
EPS 5Y-2.67%
EPS Q2Q%-3.03%
Revenue 1Y (TTM)-2.65%
Revenue growth 3Y1.62%
Revenue growth 5Y0.05%
Sales Q2Q%-2.1%
3.2 Future
Based on estimates for the next years, PHI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 17.22% on average per year.
PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.86% yearly.
EPS Next Y20.42%
EPS Next 2Y16.17%
EPS Next 3Y15.06%
EPS Next 5Y17.22%
Revenue Next Year-1.8%
Revenue Next 2Y1.14%
Revenue Next 3Y2.28%
Revenue Next 5Y3.86%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
PHI1 is valuated rather expensively with a Price/Earnings ratio of 19.77.
78.43% of the companies in the same industry are more expensive than PHI1, based on the Price/Earnings ratio.
Compared to an average S&P500 Price/Earnings ratio of 28.19, PHI1 is valued a bit cheaper.
Based on the Price/Forward Earnings ratio of 15.24, the valuation of PHI1 can be described as correct.
72.55% of the companies in the same industry are more expensive than PHI1, based on the Price/Forward Earnings ratio.
PHI1 is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 24.37, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.77 | ||
| Fwd PE | 15.24 |
4.2 Price Multiples
PHI1's Enterprise Value to EBITDA is on the same level as the industry average.
PHI1's Price/Free Cash Flow ratio is rather cheap when compared to the industry. PHI1 is cheaper than 82.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 21.08 | ||
| EV/EBITDA | 30.6 |
4.3 Compensation for Growth
PHI1's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PHI1's earnings are expected to grow with 15.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.97
PEG (5Y)N/A
EPS Next 2Y16.17%
EPS Next 3Y15.06%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 4.15%, PHI1 is a good candidate for dividend investing.
PHI1's Dividend Yield is rather good when compared to the industry average which is at 2.50. PHI1 pays more dividend than 100.00% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.28, PHI1 pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.15% |
5.2 History
The dividend of PHI1 decreases each year by -65.46%.
Dividend Growth(5Y)-65.46%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
PHI1 has negative earnings and hence a negative payout ratio. The dividend may be in danger.
DP-0.48%
EPS Next 2Y16.17%
EPS Next 3Y15.06%
KONINKLIJKE PHILIPS NV
FRA:PHI1 (1/22/2025, 7:00:00 PM)
25.5
+0.02 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners47.12%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap23.97B
Analysts71.85
Price Target29 (13.73%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.15% |
Yearly Dividend0
Dividend Growth(5Y)-65.46%
DP-0.48%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.06%
Min EPS beat(2)-13.15%
Max EPS beat(2)-6.96%
EPS beat(4)1
Avg EPS beat(4)-8.37%
Min EPS beat(4)-25.88%
Max EPS beat(4)12.53%
EPS beat(8)3
Avg EPS beat(8)19.85%
EPS beat(12)3
Avg EPS beat(12)2.62%
EPS beat(16)7
Avg EPS beat(16)5.54%
Revenue beat(2)0
Avg Revenue beat(2)-2.71%
Min Revenue beat(2)-2.95%
Max Revenue beat(2)-2.46%
Revenue beat(4)0
Avg Revenue beat(4)-3.39%
Min Revenue beat(4)-7.41%
Max Revenue beat(4)-0.75%
Revenue beat(8)2
Avg Revenue beat(8)-0.89%
Revenue beat(12)2
Avg Revenue beat(12)-1.44%
Revenue beat(16)2
Avg Revenue beat(16)-3.44%
PT rev (1m)0.52%
PT rev (3m)2.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.53%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.3%
Revenue NY rev (1m)-0.98%
Revenue NY rev (3m)-2.46%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.77 | ||
| Fwd PE | 15.24 | ||
| P/S | 1.32 | ||
| P/FCF | 21.08 | ||
| P/OCF | 13.32 | ||
| P/B | 2.02 | ||
| P/tB | N/A | ||
| EV/EBITDA | 30.6 |
EPS(TTM)1.29
EY5.06%
EPS(NY)1.67
Fwd EY6.56%
FCF(TTM)1.21
FCFY4.74%
OCF(TTM)1.92
OCFY7.51%
SpS19.29
BVpS12.64
TBVpS-1.53
PEG (NY)0.97
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.43% | ||
| ROE | -3.54% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 41.56% | ||
| FCFM | 6.27% |
ROA(3y)1.3%
ROA(5y)2.5%
ROE(3y)2.33%
ROE(5y)5.25%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-40.52%
OM growth 5Y-26.4%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.47%
GM growth 5Y-1.32%
F-Score5
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.6 | ||
| Debt/FCF | 7.27 | ||
| Debt/EBITDA | 7.18 | ||
| Cap/Depr | 51.64% | ||
| Cap/Sales | 3.66% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 181.09% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.16 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z | 1.63 |
F-Score5
WACC5.99%
ROIC/WACCN/A
Cap/Depr(3y)53.02%
Cap/Depr(5y)58.22%
Cap/Sales(3y)4.17%
Cap/Sales(5y)4.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.65%
EPS 3Y-15.7%
EPS 5Y-2.67%
EPS Q2Q%-3.03%
EPS Next Y20.42%
EPS Next 2Y16.17%
EPS Next 3Y15.06%
EPS Next 5Y17.22%
Revenue 1Y (TTM)-2.65%
Revenue growth 3Y1.62%
Revenue growth 5Y0.05%
Sales Q2Q%-2.1%
Revenue Next Year-1.8%
Revenue Next 2Y1.14%
Revenue Next 3Y2.28%
Revenue Next 5Y3.86%
EBIT growth 1Y20.11%
EBIT growth 3Y-39.56%
EBIT growth 5Y-26.36%
EBIT Next Year69.31%
EBIT Next 3Y25.78%
EBIT Next 5YN/A
FCF growth 1Y-60.7%
FCF growth 3Y-2.55%
FCF growth 5Y0.39%
OCF growth 1Y-51.1%
OCF growth 3Y-5.06%
OCF growth 5Y-1.42%